SEC Form SC 13G/A filed by I-MAB (Amendment)

$IMAB
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $IMAB alert in real time by email
SC 13G/A 1 sch13ga.htm
Page 1 of 5
CUSIP No. 44975P 103
SCHEDULE 13G/A

 

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 

 
SCHEDULE 13G
 
Under the Securities Exchange Act of 1934
(Amendment No. 4) *
 

 
I-MAB
(Name of Issuer)
 
Ordinary shares, par value US$0.0001 per share
(Title of Class of Securities)
 
44975P 103 **
(CUSIP Number)
 
December 31, 2023
(Date of the Event Which Requires Filing of this Statement)
 


Check the appropriate box to designate the rule pursuant to which this Schedule is filed :
 
☐ Rule 13d-1(b)
☒ Rule 13d-1(c)
☐ Rule 13d-1(d)
 
*
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
**
There is no CUSIP number assigned to the ordinary shares. CUSIP number 44975P 103 has been assigned to the American Depositary Shares (“ADSs”) of the Issuer, each ten (10) ADSs representing twenty three (23) ordinary shares, which are quoted on the Nasdaq Global Market under the symbol “IMAB.”
 
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provision of the Act (however, see the Notes.)
 
 

Page 2 of 5
CUSIP No. 44975P 103
SCHEDULE 13G/A
             
  1.    
 
NAME OF REPORTING PERSONS.
 
GIC Private Limited
  2.
 
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a)  ☐        (b)  ☐
 
  3.
 
SEC USE ONLY
 
  4.
 
CITIZENSHIP OR PLACE OF ORGANIZATION
 
Republic of Singapore
       
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
  
5.    
  
SOLE VOTING POWER
 
4
  
6.
  
SHARED VOTING POWER
 
0
  
7.
  
SOLE DISPOSITIVE POWER
 
4
  
8.
  
SHARED DISPOSITIVE POWER
 
0
             
  9.    
 
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
4
10.
 
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES   ☐
(See Instructions)
11.
 
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
0.0% (1)
12.
 
TYPE OF REPORTING PERSON (See Instructions)
 
CO
 

(1)
Based on 190,033,689 ordinary shares of the Issuer outstanding as of June 30, 2023, as disclosed in the Form 6-K filed by the Issuer with the Securities and Exchange Commission on August 17, 2023.
 

Page 3 of 5
CUSIP No. 44975P 103
SCHEDULE 13G/A

Item 1(a)
Name of Issuer
 
I-MAB (the “Issuer”)

Item 1(b)
Address of Issuer’s Principal Executive Offices
 
55th Floor, New Bund Center, 555 West Haiyang Road, Pudong District
Shanghai, 200124
 
People’s Republic of China
 
Item 2(a)
Name of Persons Filing
 
GIC Private Limited (“GIC”)
 
Item 2(b)
Address of Principal Business Office or, if none, Residence
 
168 Robinson Road
#37-01 Capital Tower
Singapore 068912
 
Item 2(c)
Citizenship
 
Republic of Singapore
 
Item 2(d)
Title of Class of Securities
 
Ordinary shares, par value US$0.0001 per share (the “Ordinary Shares”)
 
Item 2(e)
CUSIP Number
 
There is no CUSIP number assigned to the ordinary shares. CUSIP number 44975P 103 has been assigned to the American Depositary Shares (“ADSs”) of the Issuer, each ten (10) ADSs representing twenty three (23) ordinary shares, which are quoted on the Nasdaq Global Market under the symbol “IMAB.” 
 
Item 3
If this statement is filed pursuant to §§240.13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
 
Not applicable.
 
Item 4
Ownership

(a - c)  The aggregate number of securities and percentage of the class of securities of the Issuer beneficially owned by the Reporting Person named in Item 2(a), as well as the number of securities as to which such person is deemed to have sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, shared power to dispose or direct the disposition, is set forth in the following tables:
 
Reporting Person
No. of Securities Beneficially Owned
Percent of Class
Voting Power
Dispositive Power
   
(3)
Sole (1), (2)
Shared (1), (2)
Sole (1), (2)
Shared (1), (2)
GIC Private Limited
4
0.0%
4
0
4
0
 

(1)
GIC is a fund manager and only has 2 clients – the Government of Singapore (“GoS”) and the Monetary Authority of Singapore (“MAS”).  Under the investment management agreement with GoS, GIC has been given the sole discretion to exercise the voting rights attached to, and the disposition of, any shares managed on behalf of GoS. As such, GIC has the sole power to vote and power to dispose of 4 shares beneficially owned by it.


Page 4 of 5
CUSIP No. 44975P 103
SCHEDULE 13G/A

GIC is wholly-owned by the GoS and was set up with the sole purpose of managing Singapore’s foreign reserves. The GoS disclaims beneficial ownership of such shares.


(2)
GIC disclaims membership in a group.


(3)
Based on 190,033,689 ordinary shares of the Issuer outstanding as of June 30, 2023, as disclosed in the Form 6-K filed by the Issuer with the Securities and Exchange Commission on August 17, 2023.
 

Item 5
Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owners of more than five percent of the class of securities, check the following

Item 6
Ownership of More than Five Percent on Behalf of Another Person
 
Not applicable.

Item 7
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company
 
Not applicable.

Item 8
Identification and Classification of Members of the Group
 
Not applicable.

Item 9
Notice of Dissolution of Group
 
Not applicable.

Item 10
Certifications
 
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
 


Page 5 of 5
CUSIP No. 44975P 103
SCHEDULE 13G/A


 
SIGNATURE
 
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct as dated.
 
GIC PRIVATE LIMITED




By: /s/ Diane Liang Weishan
Name: Diane Liang Weishan
Title: Senior Vice President
Date: February 13, 2024





By: /s/ Toh Tze Meng
Name: Toh Tze Meng
Title: Senior Vice President
Date: February 13, 2024
 
Get the next $IMAB alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$IMAB

DatePrice TargetRatingAnalyst
12/9/2021$96.00Buy
Siebert Williams Shank
11/1/2021$83.00 → $85.00Buy
Needham
9/1/2021$75.00 → $95.00Buy
HC Wainwright & Co.
More analyst ratings

$IMAB
Press Releases

Fastest customizable press release news feed in the world

See more
  • I-Mab to Present at 24th Annual Needham Virtual Healthcare Conference

    ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB), a US-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab's management team will participate in 24th Annual Needham Virtual Healthcare Conference, being held April 7-10, 2025. Details are as follows: 24th Annual Needham Virtual Healthcare Conference Conference Date:April 7-10, 2025Format:Company Presentation and one-on-one meetingsPresentation Time:Monday, April 7, 2025, 8:45 to 9:25 AM ETWebcast Link:Register here   About I-Mab I-Mab (NASDAQ:IMAB) is a US-based, global biotech company, focused on the developm

    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

    ROCKVILLE, Md., March 21, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) ("I-Mab" or the "Company"), announced today that on March 19, 2025 it received a written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with the $1.00 minimum bid price requirement under the Nasdaq Listing Rules (the "Listing Rules"). Based on the closing bid price of the Company's listed securities for the period from February 3, 2025 to March 18, 2025, the Company has not met the minimum bid price requirement set forth in Listing Rule 5450(a)(1) during that period. The Notice is only a notification of deficienc

    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • I-Mab Announces Accelerated Givastomig Phase 1b Study Progress

    Enrollment completed ahead of schedule in the first dose expansion cohortMomentum continues with first patient dosed in the second expansion cohortTopline results from the 40-patient dose expansion study expected in 1H 2026 Phase 1b dose escalation data expected to be presented in 2H 2025 ROCKVILLE, Md., March 07, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that enrollment has been completed ahead of schedule in the first dose expansion cohort in the Phase 1b givastomig combination study, with continued momentum in the sec

    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

$IMAB
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$IMAB
SEC Filings

See more

$IMAB
Leadership Updates

Live Leadership Updates

See more
  • I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program

    Givastomig: a Claudin 18.2 ("CLDN18.2") x 4-1BB bispecific antibody, will be the lead clinical program following the Company's portfolio prioritizationThe Company has completed enrollment of a dose escalation study of givastomig in combination with nivolumab plus chemotherapy, and data is expected in the early second half of 2025; a 40-patient dose expansion study is now underway with data expected in early 2026Cash balance of $184.4 million (as of September 30, 2024), expected to support operations into 2027, complemented by a strengthened U.S.-based leadership team and streamlined operating modelROCKVILLE, MD, Jan. 6, 2025 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based,

    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • I-Mab Reports Third Quarter 2024 Results

    Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy dataOn track to dose first patient in randomized Phase 2 study of uliledlimab in first-line mNSCLC in 1H 2025Appointed Dr. Sean Fu as permanent CEO effective November 1, 2024Estimated cash runway into 2027, based on $184.4 million in cash and cash equivalents, and short-term investments as of September 30, 2024ROCKVILLE, Md., Nov. 14, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced financial results for the three and nine months ended

    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer

    ROCKVILLE, Md., Nov. 6, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that Sean (Xi-Yong) Fu, PhD, MBA has been appointed as the Company's permanent Chief Executive Officer ("CEO") effective November 1, 2024. Dr. Fu has served as Interim CEO since July 15, 2024. Dr. Fu will continue to serve as a member of the Board of Directors of I-Mab. "Sean's appointment serves as a significant step towards further rea

    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

$IMAB
Financials

Live finance-specific insights

See more
  • I-Mab to Release Q3 2024 Financial Results on November 14, 2024

    ROCKVILLE, Md., Oct. 31, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to release financial results for the third quarter ended September 30, 2024, on Thursday, November 14, 2024, pre-market Eastern Time. The Company will not host a conference call to discuss its third quarter 2024 financial results. The Company intends to host an investor update call in conjunction with its 2024 full-year fin

    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates

    Completed divestiture of China operationsUliledlimab IND clearance paves the way for U.S. combination studies in first-line mNSCLC (CD73 antibody)Clinical collaboration and supply agreement with Bristol Myers Squibb strengthens givastomig first-line gastric cancer combination studies (CLDN18.2 X 4-1BB bispecific)Ragistomig presentation at ASCO 2024 highlights encouraging early data (PD-L1 X 4-1BB bispecific)Well-positioned for pipeline advancement with $207.5 million in cash and cash equivalents, and short-term investments as of June 30, 2024, and cash runway expected into 2027I-Mab will hold a conference call and webcast today, August 28th, at 8:00 AM ETROCKVILLE, Md., Aug. 28, 2024 /PRNews

    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • I-Mab to Release 1H 2024 Financial Results on August 28, 2024

    Conference call to discuss financial results and recent business highlights to take place on Wednesday, August 28, 2024, at 8:00 AM ET ROCKVILLE, Md., Aug. 14, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to host a conference call and webcast on Wednesday, August 28, 2024, 8:00 AM ET to discuss financial results, pipeline progress and recent business highlights for the half year ended June 30, 2024.

    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

$IMAB
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more